Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
Neurocrine Biosciences, Inc. announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time ...
Intuit Inc. , the global financial technology platform that makes TurboTax, Credit Karma, QuickBooks, and Mailchimp, will announce its second-quarter financial results for fiscal year 2025 on February ...
Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia ...
EXCLUSIVE. According to the Nobel Prize-winning economist, Europe needs to review its innovation policy, or it will disappear ...
Sen. Brandon Shippy, R-New Plymouth, is proposing to put a 10-year pause on certain types of vaccines that were used for some ...
Discover the top 3 undervalued Life Sciences Tools & Services stocks for Thursday, January 30 based on AAII’s Stock Grades.